198 related articles for article (PubMed ID: 35066599)
1. Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.
Nosáľ V; Petrovičová A; Škorňová I; Bolek T; Dluhá J; Stančiaková L; Sivák Š; Babálová L; Hajaš G; Staško J; Kubisz P; Kurča E; Samoš M; Mokáň M
Eur J Clin Pharmacol; 2022 Apr; 78(4):557-564. PubMed ID: 35066599
[TBL] [Abstract][Full Text] [Related]
2. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G
J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628
[TBL] [Abstract][Full Text] [Related]
3. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
[TBL] [Abstract][Full Text] [Related]
4. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
[TBL] [Abstract][Full Text] [Related]
5. Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation?
Samoš M; Bolek T; Stančiaková L; Škorňová I; Ivanková J; Kovář F; Galajda P; Kubisz P; Staško J; Mokáň M
Diabetes Res Clin Pract; 2018 Jan; 135():172-177. PubMed ID: 29175298
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
[TBL] [Abstract][Full Text] [Related]
8. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
[TBL] [Abstract][Full Text] [Related]
9. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
11. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
[TBL] [Abstract][Full Text] [Related]
12. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
13. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
[TBL] [Abstract][Full Text] [Related]
14. Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints.
Zielinski GD; Teichert M; Klok FA; Rosendaal FR; Huisman MV; Cannegieter SC; Lijfering WM
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1371-1378. PubMed ID: 30443944
[TBL] [Abstract][Full Text] [Related]
15. Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation.
Jansson M; Själander S; Sjögren V; Renlund H; Norrving B; Själander A
Thromb Res; 2020 Jan; 185():135-141. PubMed ID: 31816553
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants.
Aggarwal R; Ruff CT; Virdone S; Perreault S; Kakkar AK; Palazzolo MG; Dorais M; Kayani G; Singer DE; Secemsky E; Piccini J; Tahir UA; Shen C; Yeh RW
Circulation; 2023 Sep; 148(12):936-946. PubMed ID: 37621213
[TBL] [Abstract][Full Text] [Related]
17. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
18. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
[TBL] [Abstract][Full Text] [Related]
19. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
20. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
